Pharma BD Deal Intelligence
Daiichi Sankyo Company, Limited / Plexxikon Inc.
2011 · Acquisition/Merger · $935M · Complete
Announcement Sentiment
63
Positive
Outcome Score
51
Mixed — partial payoff, real shortfalls.
Daiichi Sankyo acquired Plexxikon for $805M + $130M milestones for melanoma drug vemurafenib.
Did it work? Outcome assessment
Daiichi Sankyo / Plexxikon: Partially Achieved (Score: 59/100)
Strategic verdict
Partially Achieved
Assessment window: 5yr post-close.
Key facts
- Announced Feb 28, 2011
- Closed Apr 01, 2011
- Deal value $935M
- Deal type Acquisition/Merger
- Therapeutic area Oncology
- Key assets vemurafenib
See the full interactive analysis, sources & comparables →
← Browse all deals ·
How we score deals